Safety and efficacy of diltiazem for the treatment of atrial fibrillation with rapid ventricular response in obese patients

Diltiazem was effective and well tolerated in patients with obesity, even at lower actual-body-weight-based doses. Higher initial doses increased the likelihood of early rate control without increasing adverse events, suggesting modestly higher, individualized dosing may be safe and effective. Ideal-body-weight-based dosing better aligned with guideline targets, supporting its use in obese patients. Prospective studies are needed to determine optimal dosing strategies to maximize the efficacy and safety of diltiazem.